Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders

被引:47
作者
Waghule, Tejashree [1 ]
Rapalli, Vamshi Krishna [1 ]
Gorantla, Srividya [1 ]
Saha, Ranendra Narayan [1 ,2 ]
Dubey, Sunil Kumar [1 ]
Puri, Anu [3 ]
Singhvi, Gautam [1 ]
机构
[1] Birla Inst Technol & Sci, Dept Pharm, Ind Res Lab, Pilani Campus, Pilani, Rajasthan, India
[2] Birla Inst Technol & Sci, Dubai Campus, Pilani, U Arab Emirates
[3] Natl Canc Inst Frederick, NIH, Frederick, MD USA
关键词
Nanocarriers; nanostructured lipid carriers; psoriasis; skin diseases; targeted drug delivery; topical drug delivery; TOPICAL APPLICATION; IN-VITRO; NANOPARTICLES; PSORIASIS; NLC; NANOCARRIERS; VORICONAZOLE; MODELS; METHOTREXATE; FORMULATION;
D O I
10.2174/1381612826666200614175236
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Skin diseases affect all the age groups of people and have an impact on patients' physical, mental, and emotional status. Conventional topical preparation is limited with its efficacy due to low permeation, frequent application, and poor adherence to the therapy for prolong time. Objective: The objective of this review article is to address the emerging trends of nanotechnology derived lipidic carrier systems for an effective treatment for skin disorders. Methodology: Various research and review articles from reputed international journals were referred and compiled. Results and Discussion: Topical drug delivery systems were found to be more effective than oral and parenteral drug delivery systems for treating skin diseases due to targeted localized applications with reduced side effects. Lipid-based nanoparticles have been found to have the potential in treating skin diseases due to the biocompatibility and the versatility of the lipids. Nanostructured lipid carriers (NLCs) have gained much attention in treating skin diseases due to improved stability of the drugs, enhanced skin permeation, retention, and better therapeutic efficacy. The review summarizes the NLCs characteristics and their application for topical delivery of various therapeutics in skin disorders. NLCs have shown great potential in effective drug delivery for the treatment of psoriasis, dermatitis, bacterial infections, and skin cancer. Its cosmetic application has opened a new area for skincare. Furthermore, safety and clinical status revealed its future commercial acceptability. Conclusion: NLCs have been found as effective lipid nanocarriers for the delivery of topical therapeutics.
引用
收藏
页码:4569 / 4579
页数:11
相关论文
共 103 条
[1]   Skin models for the testing of transdermal drugs [J].
Abd, Eman ;
Yousef, Shereen A. ;
Pastore, Michael N. ;
Telaprolu, Krishna ;
Mohammed, Yousuf H. ;
Namjoshi, Sarika ;
Grice, Jeffrey E. ;
Roberts, Michael S. .
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2016, 8 :163-176
[2]   Anti-inflammatory sunscreen nanostructured lipid carrier formulations [J].
Abdel-Salam, Fatma S. ;
Ammar, Hussein O. ;
Elkheshen, Seham A. ;
Mahmoud, Azza A. .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2017, 37 :13-19
[3]   Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate [J].
Abdel-Salam, Fatma S. ;
Mahmoud, Azza A. ;
Ammar, Hussein O. ;
Elkheshen, Seham A. .
JOURNAL OF LIPOSOME RESEARCH, 2017, 27 (01) :41-55
[4]   Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis [J].
Agrawal, Yogeeta ;
Petkar, Kailash C. ;
Sawant, Krutika K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 401 (1-2) :93-102
[5]  
AJAY P., 2010, International Journal of Pharmacy and Pharmaceutical Sciences, V2, P30, DOI [DOI 10.1016/J.BBRC.2022.01.120, DOI 10.1016/B978-0-12-405870-5.00002-5]
[6]  
Akhtar N, 2017, B FAC PHARM CAIRO, V55, P1, DOI [10.1016/j.bfopcu.2016.12.003, DOI 10.1016/J.BFOPCU.2016.12.003]
[7]   Nanostructured Lipid Carrier for Topical Application of N-Acetyl Glucosamine [J].
Aliasgharlou, Lavin ;
Ghanbarzadeh, Saeed ;
Azimi, Hamideh ;
Zarrintan, Mohammad Hossein ;
Hamishehkar, Hamed .
ADVANCED PHARMACEUTICAL BULLETIN, 2016, 6 (04) :581-587
[8]  
Almousallam M, 2015, INT NANO LETT, V5, P241, DOI 10.1007/s40089-015-0161-8
[9]  
Andrea P, 2016, SCI PROGRAM, V7, P9554
[10]  
[Anonymous], 2016, INT J CURR PHARM REV